Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Abstract Background Overall survival (OS) is the gold standard to assess novel therapeutics to treat cancer. However, to identify early efficacy and speed up drug approval, trials have used progression-free survival (PFS) as a surrogate endpoint (SE). Herein, we aimed to examine if PFS could functio...

Full description

Bibliographic Details
Main Authors: Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Cancer
Subjects:
Surrogate
Progression-free survival
PD-1/PD-L1 inhibitors
Advanced esophageal squamous cell carcinoma
Online Access:https://doi.org/10.1186/s12885-023-10613-y

Similar Items

Similar Items